Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F-Florastamin PET/CT in Prostate Cancer
NCT06011304Phase 3Completed
- Start
- Oct 2023
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of 18f-florastamin in prostate cancer (PCa). Primary endpoint: Specificity at 28 days. Started Oct 2023; status: completed.
02
Drugs
18f-florastamin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06011304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06011304.